Eli Lilly & Co. is best positioned to dominate the fast-growing U.S. market for obesity drugs into the 2030s, BMO Capital Markets analysts said in a report.
Novo Nordisk A/S (NYSE:NVO – Get Free Report) was downgraded by research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a note issued to investors on Thursday. NVO has been the subject of several other research reports. HSBC assumed coverage on shares of Novo Nordisk A/S in a research note on […]